Literature DB >> 2192865

Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease.

P D Delmas1.   

Abstract

There is not yet an ideal marker of bone formation, but circulating BGP is the most satisfactory at present. New developments include the use of sheep BGP64 and human BGP85 as an immunogen and monoclonal antibodies, which may recognize fragments of BGP released during resorption. The specific measurement of bone alkaline phosphatase and the assay of procollagen fragments and of other noncollagenous bone-related proteins will allow a more precise assessment of the complex osteoblastic functions in normal and pathologic conditions. Finding a sensitive and specific marker of resorption is a challenge because all constituents of bone matrix are likely to be degraded into minute peptides during osteoclastic bone resorption. The measurement of pyridinium crosslinks and possibly of tartrate-resistant acid phosphate by a bone-specific monoclonal antibody are the most tangible improvements in this area. These markers need to be validated by comparison with data obtained by direct measurement of bone turnover on iliac crest biopsy. It should be remembered, however, that circulating markers reflect the overall activity of the whole skeleton, including the cortical, subcortical, and trabecular envelopes, which have different remodeling rates in normal and abnormal states. A circulating marker will not detect a specific defect of the cellular activity of one compartment of bone if the summated turnover of the skeleton is unchanged. Conversely, bone histomorphometry is limited to a small area of the trabecular envelope but allows detection of a specific defect at the cellular level. These differences should be kept in mind, as there is growing evidence that, for example, bone mass and bone turnover of osteoporotic patients before and during treatment vary in different appendicular/axial and cortical/trabecular compartments. Finally, a single marker might be valuable in some diseases and not in others (such as serum BGP in Paget's disease of bone). Despite these difficulties, significant advances have been made in the last few years in the bone marker field. In the future, the development of a battery of several bone-specific markers that indicate various aspects of the complex mechanisms of bone formation, resorption, and mineralization is likely to provide new tools for the diagnosis and management of bone diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192865

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  29 in total

1.  Ambient Ionization Mass Spectrometry Measurement of Aminotransferase Activity.

Authors:  Xin Yan; Xin Li; Chengsen Zhang; Yang Xu; R Graham Cooks
Journal:  J Am Soc Mass Spectrom       Date:  2017-01-31       Impact factor: 3.109

2.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Authors:  J A Kanis
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

3.  Osteopenia and decreased bone formation in osteonectin-deficient mice.

Authors:  A M Delany; M Amling; M Priemel; C Howe; R Baron; E Canalis
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.

Authors:  Y Nagata; M Inaba; Y Imanishi; H Okazaki; S Yamada; K Mori; S Shoji; H Koyama; S Okuno
Journal:  Osteoporos Int       Date:  2014-11-18       Impact factor: 4.507

5.  Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.

Authors:  P Szulc; M C Chapuy; P J Meunier; P D Delmas
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  Bone changes in postmenopausal Spanish women.

Authors:  H Rico; E R Hernández; M Revilla; L F Villa; M Alvarez de Buergo; E Cuende
Journal:  Calcif Tissue Int       Date:  1993-02       Impact factor: 4.333

7.  Indicators of bone formation in weight lifters.

Authors:  M K Karlsson; P Vergnaud; P D Delmas; K J Obrant
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

8.  Serum osteocalcin and fracture susceptibility in elderly women.

Authors:  K Akesson; S Ljunghall; P Gärdsell; I Sernbo; K J Obrant
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

Review 9.  Biochemical markers of bone turnover for the clinical investigation of osteoporosis.

Authors:  P D Delmas
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

10.  Enhancement of osteoblast proliferative capacity by growth factor-like molecules in bear serum.

Authors:  Michael Overstreet; Timothy Floyd; Anna Polotsky; David S Hungerford; Carmelita G Frondoza
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jan-Feb       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.